New licence provides CHUM access to the ERS CRISPR/Cas9 patent portfolio. DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ — ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with the CHUM Research Centre (‘(CRCHUM),’). This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio. Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology. The CHUM Research Centre is the largest research centre in the field of biomedical